Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Abstract Overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is critical in combating EGFR-mutant non-small cell lung cancer (NSCLC). We tried to construct a novel therapeutic strategy to conquer the resistance to second-and third-generation EGFR...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Akiko Takahashi, Masahiro Seike, Mika Chiba, Satoshi Takahashi, Shinji Nakamichi, Masaru Matsumoto, Susumu Takeuchi, Yuji Minegishi, Rintaro Noro, Shinobu Kunugi, Kaoru Kubota, Akihiko Gemma
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Osimertinib
Afatinib
Ankyrin Repeat Domain (ANKRD1)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs)
EGFR-mutant NSCLC Patients
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/2d4c5449621342aa816f7c0089346a66
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares